| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C28H37NO4S |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
CI-1029 inhibits HIV-1 protease, with a human IC50 of 0.11 nM. It is active against both wild-type and mutant HIV proteases and shows antiviral effects against HIV, including multiple drug-resistant strains, with an EC50 of 6.31 μM measured in the presence of 30% human serum. It can be used in studies of HIV infection and acquired immunodeficiency syndrome (AIDS)[1]. The compound has the molecular formula C28H37NO4S and a molecular weight of 483.66 g/mol.
Physical & Chemical Properties
| CAS Number | 207736-05-8 |
|---|---|
| Molecular Formula | C28H37NO4S |
| Molecular Weight | 483.66 g/mol |
| SMILES | NC(C=C1)=CC=C1CC[C@]2(CC(O)=C(C(O2)=O)SC3=C(C=C(C(C)=C3)CO)C(C)(C)C)C(C)C |
| Target | HIV-1 Protease |
| Signaling Pathway | Anti-infection; Metabolic Enzyme/Protease |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
HIV-1 Protease 0.11 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
At 60 min, CI-1029 potently inhibits purified HIV-1 protease, at an IC50 of 0.11 nM and Ki of 0.11 nM[1]. In HIV-IIIB-infected CEM cells, CI-1029 gives protection at an EC50 of 0.20 μM, while its cytotoxicity in uninfected CEM cells is low (TC50 of 210 μM), yielding a therapeutic index of 1000[1]. With 30% human serum present, CI-1029 still protects HIV-infected cells, at an EC50 of 6.31 μM[1]. Against multiple protease-resistant HIV strains in PBMCs, CI-1029 stays potent, with a fold increase in EC50 of ≤2 relative to wild-type virus[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
